1-9 of 9
emicizumab
Close
Sort by
Journal Articles

Thrombosis and novel hemophilia therapies: the fine line between clotting and bleeding

Maureane Hoffman
Journal: Blood Advances
Blood Adv (2021) 5 (18): 3736.
https://doi.org/10.1182/bloodadvances.2021004802
Published: 2021
Includes: Supplemental data
Journal Articles

First report of emicizumab use in a female patient with severe hemophilia A

Clinical Trials & Observations
Géraldine Verstraete, Catherine Lambert, Cedric Hermans
Journal: Blood Advances
Blood Adv (2020) 4 (13): 2950–2952.
https://doi.org/10.1182/bloodadvances.2020002364
Published: 2020
Journal Articles

Laboratory monitoring of hemophilia A treatments: new challenges

Clinical Trials & Observations
Peter J. Lenting
Journal: Blood Advances
Blood Adv (2020) 4 (9): 2111–2118.
https://doi.org/10.1182/bloodadvances.2019000849
Published: 2020
Journal Articles

Total knee replacement with and without emicizumab: a unique comparison of perioperative management

Clinical Trials & Observations
Matthew S. Evans, Charles Davis, III, M. Elaine Eyster
Journal: Blood Advances
Blood Adv (2020) 4 (5): 855–857.
https://doi.org/10.1182/bloodadvances.2019001060
Published: 2020
Journal Articles

Efficacy of emicizumab in a pediatric patient with type 3 von Willebrand disease and alloantibodies

Angela C. Weyand, Veronica H. Flood, Jordan A. Shavit, Steven W. Pipe
Journal: Blood Advances
Blood Adv (2019) 3 (18): 2748–2750.
https://doi.org/10.1182/bloodadvances.2019000656
Published: 2019
Journal Articles

Emicizumab use in major orthopedic surgery

Clinical Trials & Observations
Craig D. Seaman, Margaret V. Ragni
Journal: Blood Advances
Blood Adv (2019) 3 (11): 1722–1724.
https://doi.org/10.1182/bloodadvances.2019000228
Published: 2019
Journal Articles

Emicizumab should be prescribed independent of immune tolerance induction

Sandra Le Quellec, Claude Negrier
Journal: Blood Advances
Blood Adv (2018) 2 (20): 2783–2786.
https://doi.org/10.1182/bloodadvances.2018015859
Published: 2018
Journal Articles

Implementing emicizumab in hemophilia inhibitor management: emicizumab should be prescribed after tolerance

Guy Young
Journal: Blood Advances
Blood Adv (2018) 2 (20): 2780–2782.
https://doi.org/10.1182/bloodadvances.2018015842
Published: 2018
Journal Articles

Long-term safety and efficacy of emicizumab in a phase 1/2 study in patients with hemophilia A with or without inhibitors

Clinical Trials & Observations
Midori Shima, Hideji Hanabusa, Masashi Taki, Tadashi Matsushita, Tetsuji Sato, Katsuyuki Fukutake, Ryu Kasai, Koichiro Yoneyama, Hiroki Yoshida, Keiji Nogami
Journal: Blood Advances
Blood Adv (2017) 1 (22): 1891–1899.
https://doi.org/10.1182/bloodadvances.2017006684
Published: 2017
Includes: Supplemental data